Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

Delayed Quote. Delayed  - 09/30 05:31:48 pm
168.2 CHF   -0.12%
09/29 ACTELION : to investigate all-oral combination therapy for patients ..
08/31ACTELION LTD : The calm spell can be taken advantage of to put on ne..
08/22 ACTELION : completes first-line share purchase program
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20142015Delta
CHF (in Million)%CHF (in Million)%
Drugs1,958100%2,045100% +4.45%
Sales per Regions
20142015Delta
CHF (in Million)%CHF (in Million)%
United States879.2444.9%1,02650.1% +16.64%
Europe687.8235.1%633.2031% -7.94%
Other360.5218.4%167.868.2% -53.44%
Switzerland30.301.5%28.391.4% -6.32%
Japan--190.069.3%-
Managers
NameAgeSinceTitle
Jean-Paul Clozel611997Chief Executive Officer & Executive Director
Jean-Pierre Garnier682011Chairman
Otto Schwarz612008Chief Operating Officer & Executive Vice President
André C. Muller, MBA532013Chief Financial Officer & Executive Vice President
Martine Clozel, MD611997Chief Scientific Officer & Senior Vice President
Michael Jacobi, PhD632009Independent Non-Executive Director
Jean Pierre Malo CFA, MBA622004Independent Non-Executive Director
Juhani Anttila62-Independent Non-Executive Director
Robert J. Bertolini, CPA53-Independent Non-Executive Director
Peter Gruss, PhD672012Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 107,761,427 89,519,496 83.1% 8,943,000 8.3% 83.1%
Shareholders
NameEquities%
Rudolf Maag, MBA 5,467,305 5.07%
Jean-Paul Clozel 5,418,507 5.03%
Actelion Ltd. 3,257,940 3.02%
Fidelity Management & Research Co. 2,959,331 2.75%
Wellington Management Co. LLP 2,774,776 2.57%
UBS AG (Investment Management) 2,164,254 2.01%
BlackRock Investment Management (UK) Ltd. 2,078,261 1.93%
Artisan Partners LP 2,065,771 1.92%
The Vanguard Group, Inc. 1,965,329 1.82%
Bellevue Asset Management AG 1,702,164 1.58%
Holdings
NameEquities%Valuation
Actelion Ltd (ATLN) 3,257,9403.02%542,796,554 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ACTELION LTD21.70%18 780
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
CELGENE CORPORATION-14.19%79 659
REGENERON PHARMACEUTIC..-25.15%42 787
VERTEX PHARMACEUTICALS..-32.45%21 061
GENMAB A/S22.94%10 223
TESARO INC92.24%5 166
HUALAN BIOLOGICAL ENGI..--.--%5 161
TONGHUA DONGBAO PHARMA..-83.41%4 814
NEUROCRINE BIOSCIENCES..-11.03%4 366
INTERCEPT PHARMACEUTIC..7.28%3 962
BEIJING SL PHARMACEUTI..--.--%3 397
CHINA BIOLOGIC PRODUCT..-13.15%3 327
JUNO THERAPEUTICS INC-31.79%3 311
GW PHARMACEUTICALS PLC109.08%3 243
SAREPTA THERAPEUTICS I..58.06%3 225
PEPTIDREAM INC40.59%3 063
EXELIXIS, INC.117.73%2 828
KITE PHARMA INC-9.15%2 800
BIOCON LTD87.48%2 773
Sector Bio Therapeutic Drugs
Actelion Ltd : Connections
Newman's Own Foundation
CFA Institute
Actelion Pharmaceuticals Hellas SA
Alzheon, Inc.
Actelion Pharmaceuticals Italia SRL
Max Planck Institute For Biophysical Chemistry
Actelion Pharmaceuticals Japan Ltd.
Cerenis Therapeutics, Inc.
Actelion Pharmaceuticals Korea Ltd.
Hilti Martin Family Trust
Avalon Advisors LLC
Society of Financial Analysts of Houston
ArgYou AG
ValCrea AG
Deutsche Akademie der Technikwissenschaften eV
Actelion Pharmaceuticals UK Ltd.
Anttila & Co. Advisors
Actelion Pharmaceuticals Sverige AB
Martin Hilti Family Trust
Deutsche Forschungsgemeinschaft
Hilti AG
Deutsche Akademie der Naturforscher Leopoldina eV
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  ATLN:VX
- Reuters Code :  ATLN.VX
- Datastream Code :  S:ATLN
© 2016 People , Fundamentals and Ownership    © 2016 Cofisem